Related Experiment Video
Updated: Jan 5, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Challenges in conducting trials for pediatric tuberculous meningitis: lessons from the field
M Paradkar1, D B Devaleenal2, T Mvalo3
1Byramjee Jeejeebhoy Government Medical College-Johns Hopkins Clinical Research Site, Pune.
Insights
Conducting clinical trials for pediatric tuberculous meningitis (TBM) is difficult due to diagnostic and logistical challenges. Sharing these insights can improve future TBM treatment research for children.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Trial Methodology
- Tuberculosis Research
Background:
- Tuberculous meningitis (TBM) is a severe infection in children with significant long-term disabilities.
- There is a critical need for evidence-based treatment guidelines for pediatric TBM.
- The TBM-KIDS trial aimed to address this gap by evaluating antimicrobial agents.
Purpose of the Study:
- To identify and describe the challenges encountered during the implementation of the first randomized clinical trial for pediatric TBM.
- To provide insights for improving the design and execution of future TBM clinical trials in children.
Main Methods:
- The study utilized data from trial reports, case report forms, study diaries, and team communications.
- Challenges were reviewed, categorized, and detailed.
- Data collection spanned 17 months across three tertiary referral centers in India and Malawi.
Main Results:
- Low enrollment rate (<1%) with only 21 out of 3371 assessed children meeting criteria.
- Significant challenges included diagnostic difficulties, patient management, large catchment areas, adverse event attribution, and drug-related issues (cost, expiry).
- Adaptation of assessment tools and specialized care for caregivers and children were necessary.
Conclusions:
- Pediatric TBM clinical trials are complex but essential for improving patient outcomes.
- Sharing implementation challenges can foster community-based solutions.
- Addressing these challenges is crucial for advancing treatments for at-risk pediatric populations.
Abstract:
SETTING: TBM-KIDS is a phase I/II trial enrolling children with tuberculous meningitis (TBM) in three tertiary referral centers in India and Malawi.OBJECTIVE: To describe the challenges encountered in conducting the first randomized clinical trial of antimicrobial agents in pediatric TBM.DESIGN: The sources of the data were primarily monthly trial reports, non-enrollment case report forms, study diaries and registers maintained for recruitment, experiences shared by key team members during regular study calls and comments from site review visits. We reviewed, broadly categorized, and describe in detail the challenges encountered by study teams in trial implementation.RESULTS: Over 17 months, 3371 children with clinical presentations consistent with meningoencephalitis or undergoing lumbar puncture were assessed for eligibility; 21 (<1%) met enrollment criteria. We encountered challenges related to diagnosis, management of sick children, large catchment areas, adverse event attribution, concomitant medications, infrastructure requirements, expensive pediatric formulations with short expiry, and detection of treatment response in a highly variable disease across the age continuum. Training and adaptation of tools for neurocognitive and neurologic function assessment were necessary. Special care was undertaken to explain study participation to distraught caregivers and manage children longitudinally.CONCLUSION: Interventional trials in pediatric TBM are challenging but are critically important for improving the treatment of a disease that disables children physically, cognitively and emotionally. Sharing these challenges may help to address them more effectively as a TB research community and to advance treatments for this at-risk population.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pharmacokinetics in Pediatric Patients: Drug Excretion

